Triphasic oral contraceptive
Patent 4544554 Issued on October 1, 1985. Estimated Expiration Date: 
May 4, 2004. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 4, 2004. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesFollicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system Multi-phase combination-type sequential preparation for oral contraception and method of oral contraception Patent #: 4378356 InventorAssigneeApplicationNo. 06/607038 filed on 05/04/1984US Classes:514/170, Plural Compounds containing cyclopentanohydrophenanthrene ring systems514/177, Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/182Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring systemExaminersPrimary: Roberts, Elbert L.Attorney, Agent or FirmInternational ClassA61K 31/565 (20060101)AbstractA method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 6-8 days without administering either an estrogen or a progestogen. | |
